ArticleBiomedical optics express2026
Longitudinal drug response assessment of tumor organoids based on optical attenuation coefficient and multi-dimensional morphological characterization.
Article in Biomedical optics express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-derived tumor organoids (PDTOs) are vital for precision oncology, but standard drug screening methods, including adenosine triphosphate (ATP) assays, are destructive and prevent longitudinal monitoring. Optical coherence tomography (OCT) offers non-destructive 3D imaging, capturing morphological features and tissue attenuation characteristics via the optical attenuation coefficient (OAC). Here, we propose a non-destructive evaluation framework for tumor organoids that fuses OAC and multi-dimensional morphological features. Using intrahepatic cholangiocarcinoma (iCCA) PDTOs treated with icaritin, we found that OAC exhibited a significant dose-dependent increase (up to 32.8% at 80 μM compared to control), accompanied by a morphological transition of cystic organoids into solid phenotypes. By integrating these features via K-means++ clustering and principal component analysis, we constructed a relative growth score. This fusion score correlated strongly with the ATP gold standard (Pearson correlation coefficient
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.